Clinical Trial Update: C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 study of C752 in patients with refractory/relapsed B-cell non-Hodgkin lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• C752

Snippet

Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Conditions: Lymphoma, B-Cell, CAR-T | Phase 1 | Status: TERMINATED